Cargando…

Foam Cell Specific LXRα Ligand

OBJECTIVE: The liver X receptor α (LXRα) is a ligand-dependent nuclear receptor and the major regulator of reverse cholesterol transport in macrophages. This makes it an interesting target for mechanistic study and treatment of atherosclerosis. METHODS AND RESULTS: We optimized a promising stilbenoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldmann, Radmila, Geikowski, Anne, Weidner, Christopher, Witzke, Annabell, Kodelja, Vitam, Schwarz, Thomas, Gabriel, Mario, Erker, Thomas, Sauer, Sascha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581588/
https://www.ncbi.nlm.nih.gov/pubmed/23451202
http://dx.doi.org/10.1371/journal.pone.0057311
_version_ 1782260447326502912
author Feldmann, Radmila
Geikowski, Anne
Weidner, Christopher
Witzke, Annabell
Kodelja, Vitam
Schwarz, Thomas
Gabriel, Mario
Erker, Thomas
Sauer, Sascha
author_facet Feldmann, Radmila
Geikowski, Anne
Weidner, Christopher
Witzke, Annabell
Kodelja, Vitam
Schwarz, Thomas
Gabriel, Mario
Erker, Thomas
Sauer, Sascha
author_sort Feldmann, Radmila
collection PubMed
description OBJECTIVE: The liver X receptor α (LXRα) is a ligand-dependent nuclear receptor and the major regulator of reverse cholesterol transport in macrophages. This makes it an interesting target for mechanistic study and treatment of atherosclerosis. METHODS AND RESULTS: We optimized a promising stilbenoid structure (STX4) in order to reach nanomolar effective concentrations in LXRα reporter-gene assays. STX4 displayed the unique property to activate LXRα effectively but not its subtype LXRβ. The potential of STX4 to increase transcriptional activity as an LXRα ligand was tested with gene expression analyses in THP1-derived human macrophages and oxLDL-loaded human foam cells. Only in foam cells but not in macrophage cells STX4 treatment showed athero-protective effects with similar potency as the synthetic LXR ligand T0901317 (T09). Surprisingly, combinatorial treatment with STX4 and T09 resulted in an additive effect on reporter-gene activation and target gene expression. In physiological tests the cellular content of total and esterified cholesterol was significantly reduced by STX4 without the undesirable increase in triglyceride levels as observed for T09. CONCLUSIONS: STX4 is a new LXRα-ligand to study transcriptional regulation of anti-atherogenic processes in cell or ex vivo models, and provides a promising lead structure for pharmaceutical development.
format Online
Article
Text
id pubmed-3581588
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35815882013-02-28 Foam Cell Specific LXRα Ligand Feldmann, Radmila Geikowski, Anne Weidner, Christopher Witzke, Annabell Kodelja, Vitam Schwarz, Thomas Gabriel, Mario Erker, Thomas Sauer, Sascha PLoS One Research Article OBJECTIVE: The liver X receptor α (LXRα) is a ligand-dependent nuclear receptor and the major regulator of reverse cholesterol transport in macrophages. This makes it an interesting target for mechanistic study and treatment of atherosclerosis. METHODS AND RESULTS: We optimized a promising stilbenoid structure (STX4) in order to reach nanomolar effective concentrations in LXRα reporter-gene assays. STX4 displayed the unique property to activate LXRα effectively but not its subtype LXRβ. The potential of STX4 to increase transcriptional activity as an LXRα ligand was tested with gene expression analyses in THP1-derived human macrophages and oxLDL-loaded human foam cells. Only in foam cells but not in macrophage cells STX4 treatment showed athero-protective effects with similar potency as the synthetic LXR ligand T0901317 (T09). Surprisingly, combinatorial treatment with STX4 and T09 resulted in an additive effect on reporter-gene activation and target gene expression. In physiological tests the cellular content of total and esterified cholesterol was significantly reduced by STX4 without the undesirable increase in triglyceride levels as observed for T09. CONCLUSIONS: STX4 is a new LXRα-ligand to study transcriptional regulation of anti-atherogenic processes in cell or ex vivo models, and provides a promising lead structure for pharmaceutical development. Public Library of Science 2013-02-25 /pmc/articles/PMC3581588/ /pubmed/23451202 http://dx.doi.org/10.1371/journal.pone.0057311 Text en © 2013 Feldmann et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Feldmann, Radmila
Geikowski, Anne
Weidner, Christopher
Witzke, Annabell
Kodelja, Vitam
Schwarz, Thomas
Gabriel, Mario
Erker, Thomas
Sauer, Sascha
Foam Cell Specific LXRα Ligand
title Foam Cell Specific LXRα Ligand
title_full Foam Cell Specific LXRα Ligand
title_fullStr Foam Cell Specific LXRα Ligand
title_full_unstemmed Foam Cell Specific LXRα Ligand
title_short Foam Cell Specific LXRα Ligand
title_sort foam cell specific lxrα ligand
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581588/
https://www.ncbi.nlm.nih.gov/pubmed/23451202
http://dx.doi.org/10.1371/journal.pone.0057311
work_keys_str_mv AT feldmannradmila foamcellspecificlxraligand
AT geikowskianne foamcellspecificlxraligand
AT weidnerchristopher foamcellspecificlxraligand
AT witzkeannabell foamcellspecificlxraligand
AT kodeljavitam foamcellspecificlxraligand
AT schwarzthomas foamcellspecificlxraligand
AT gabrielmario foamcellspecificlxraligand
AT erkerthomas foamcellspecificlxraligand
AT sauersascha foamcellspecificlxraligand